GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SYNBIOTIC SBX.DE · EUR

Health Care · XETRA · 🇩🇪 Germany

Compare

0.13

-7.18%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2024

Revenue

€14.3m

FY2018FY2024

Net income

−€9.7m

FY2018FY2024

Free cash flow

−€726,066

FY2018FY2024

Shareholders' equity

€22.9m

FY2018FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue€14.3m€3.9m€8.2m€8.6m€5.4m——
Gross profit€4.9m€1.5m€3.6m€4.8m€3.7m——
Operating income−€10.5m−€11.0m−€24.9m−€11.4m−€720,708−€13,429−€822
Net income−€9.7m−€10.6m−€24.4m−€12.7m−€880,389−€13,429−€822
Diluted earnings per share-1.86-1.56-5.82-3.41-0.33-0.00-0.00

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets€45.7m€34.9m€40.6m€60.6m€35.0m€238,249€249,678
Cash and short-term investments€543,174€89,212€3.0m€5.2m€6.0m€13,249—
Total liabilities€24.7m€19.6m€17.8m€23.9m€9.5m€2,500—
Debt€5.5m€3.7m€4.5m€3.4m€366,883——
Shareholders' equity€22.9m€15.8m€22.6m€35.0m€25.5m€235,749€249,178
Shares outstanding5m7m4m4m3m7m7m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−€503,126−€2.9m−€7.0m−€5.1m−€1.3m−€11,428−€11,428
Capital spending−€222,940−€19,181−€478,154−€365,612−€2.1m−€17,847−€17,846
Free cash flow−€726,066−€2.9m−€7.5m−€5.5m−€3.4m−€29,275−€29,274

Latest quarters

By quarter end

Jun 2024Mar 2024Jun 2022Jun 2021Dec 2020Jun 2020
Revenue€3,550€3,550€18,514€48,835€5.4m€50,000
Gross profit€1,452€1,452€18,514€48,835€5.4m€50,000
Operating income−€971,887€534−€1.2m−€491,290−€761,340−€97,460
Net income−€684,778−€992−€1.3m−€438,232−€782,932−€97,456
Diluted earnings per share-0.13-0.00-0.31-0.12-0.29-0.04
Total assets€58.2m—€55.2m€44.4m€35.0m€23.3m
Cash and short-term investments€69,884€2,068€309,325€2.4m€6.0m€359,735
Debt————€114,884—
Shareholders' equity€47.2m€15,327€52.4m€43.2m€25.5m€16.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue18.3%——
Operating income-2.7%279.3%—
Net income-8.6%273.2%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin35.1%42.1%——
Operating margin-118.5%-165.4%——
Net margin-112.0%-164.2%——

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021
Price to earnings-0.6-0.5-0.5-2.2
Price to sales0.41.41.43.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.